Chief Commercial Officer · Myovant Sciences Ltd. (MYOV)

Lauren Merendino

FY2021 is the first fiscal year CompBrief holds for Lauren Merendino as a named executive officer of Myovant Sciences; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$3,463,677

Salary $461,721Stock awards $1,399,986

4th of 4 named executive officers at Myovant Sciences by FY2021 total.

4 named officers on file for Myovant Sciences, FY2021

Lauren Merendino’s pay file — $29

  • 1 fiscal year of pay, line by line
  • MYOV’s disclosed peer group of 17 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Myovant Sciences’s whole pay program stands against its peers

  • Myovant Sciences’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on MYOV→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed July 28, 2022 (DEF 14A).

Free

Get Lauren Merendino’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Lauren Merendino compensation by year

Myovant Sciences Summary Compensation Table · the one fiscal year held
In US dollars, as Myovant Sciences reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021
Salary$461,721
Bonus$0
Stock awards$1,399,986
Option awards$1,425,545
Non-equity incentive$175,000
Pension and deferred compensation$0
All other$1,425
Total$3,463,677

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Myovant Sciences Ltd. DEF 14A filed July 28, 2022, accession 0001140361-22-027161, and prior-year filings.

How this page was built: the Myovant Sciences Ltd. filed document, accession 0001140361-22-027161. Every figure is read from that document and cited to the page and table it appears in. Filed July 28, 2022.

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
RSU78,299$1,042,943—
Option123,300—$17.88

Per the Outstanding Equity Awards at Fiscal Year-End table in Myovant Sciences Ltd.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.

Myovant Sciences’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
David MarekPrincipal Executive Officer$6,247,509
Uneek MehraPrincipal Financial Officer$5,164,872
Frank KarbeFormer Principal Financial and Accounting Officer$4,451,137
Lauren Merendino · this pageChief Commercial Officer$3,463,677

The full Myovant Sciences compensation record

free company brief

This page is one person within Myovant Sciences's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Myovant Sciences's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Lauren Merendino's compensation dossier · One-time report. No refunds.